Treatment of dry age-related macular degeneration

Giuseppe Querques; Philip J. Rosenfeld; Edoardo Cavallero; Enrico Borrelli; Federico Corvi; Lea Querques; Francesco M. Bandello; Marco A. Zarbin

doi:10.1159/000363187

Treatment of dry age-related macular degeneration

Giuseppe Querques, Philip J. Rosenfeld, Edoardo Cavallero, Enrico Borrelli, Federico Corvi, Lea Querques, Francesco M. Bandello, Marco A. Zarbin

Research output: Contribution to journal › Review article › peer-review

39 Scopus citations

Abstract

A number of different approaches are under development for treating nonexudative manifestations of age-related macular degeneration (AMD). Some interventions target specific pathways that are believed to play a role in AMD pathogenesis, e.g. oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β-amyloid accumulation), impaired choroidal blood flow, and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e.

Original language	English (US)
Pages (from-to)	107-115
Number of pages	9
Journal	Ophthalmic Research
Volume	52
Issue number	3
DOIs	https://doi.org/10.1159/000363187
State	Published - Nov 19 2014

All Science Journal Classification (ASJC) codes

Ophthalmology
Sensory Systems
Cellular and Molecular Neuroscience

Keywords

Age-related macular degeneration
Drugs
Drusen
Geographic atrophy
Neurotrophic factors
Oxidative damage
Pathway
Stem cells
Treatment
Visual cycle

Access to Document

10.1159/000363187

Cite this

@article{f1697f8cab43406188db98f3e569030a,

title = "Treatment of dry age-related macular degeneration",

abstract = "A number of different approaches are under development for treating nonexudative manifestations of age-related macular degeneration (AMD). Some interventions target specific pathways that are believed to play a role in AMD pathogenesis, e.g. oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β-amyloid accumulation), impaired choroidal blood flow, and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e.",

keywords = "Age-related macular degeneration, Drugs, Drusen, Geographic atrophy, Neurotrophic factors, Oxidative damage, Pathway, Stem cells, Treatment, Visual cycle",

author = "Giuseppe Querques and Rosenfeld, {Philip J.} and Edoardo Cavallero and Enrico Borrelli and Federico Corvi and Lea Querques and Bandello, {Francesco M.} and Zarbin, {Marco A.}",

note = "Publisher Copyright: {\textcopyright} 2014 S. Karger AG, Basel.",

year = "2014",

month = nov,

day = "19",

doi = "10.1159/000363187",

language = "English (US)",

volume = "52",

pages = "107--115",

journal = "Ophthalmic Research",

issn = "0030-3747",

publisher = "S. Karger AG",

number = "3",

}

TY - JOUR

T1 - Treatment of dry age-related macular degeneration

AU - Querques, Giuseppe

AU - Rosenfeld, Philip J.

AU - Cavallero, Edoardo

AU - Borrelli, Enrico

AU - Corvi, Federico

AU - Querques, Lea

AU - Bandello, Francesco M.

AU - Zarbin, Marco A.

PY - 2014/11/19

Y1 - 2014/11/19

N2 - A number of different approaches are under development for treating nonexudative manifestations of age-related macular degeneration (AMD). Some interventions target specific pathways that are believed to play a role in AMD pathogenesis, e.g. oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β-amyloid accumulation), impaired choroidal blood flow, and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e.

AB - A number of different approaches are under development for treating nonexudative manifestations of age-related macular degeneration (AMD). Some interventions target specific pathways that are believed to play a role in AMD pathogenesis, e.g. oxidative damage, lipofuscin accumulation, chronic inflammation (including complement activation), extracellular matrix changes (e.g. β-amyloid accumulation), impaired choroidal blood flow, and apoptosis. In principle, these therapies can be combined ('combination therapy'), which may lead to synergistic effects that include better visual outcome, less likelihood for 'escape' (i.e.

KW - Age-related macular degeneration

KW - Drugs

KW - Drusen

KW - Geographic atrophy

KW - Neurotrophic factors

KW - Oxidative damage

KW - Pathway

KW - Stem cells

KW - Treatment

KW - Visual cycle

UR - http://www.scopus.com/inward/record.url?scp=84910643156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910643156&partnerID=8YFLogxK

U2 - 10.1159/000363187

DO - 10.1159/000363187

M3 - Review article

C2 - 25228171

AN - SCOPUS:84910643156

SN - 0030-3747

VL - 52

SP - 107

EP - 115

JO - Ophthalmic Research

JF - Ophthalmic Research

IS - 3

ER -

Treatment of dry age-related macular degeneration

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this